BLCO241220C30000
- 0.25
- 0.000.00%
Bausch + Lomb Corp. Newsroom
BofA Securities Downgrades Bausch + Lomb Corp.(BLCO.US) to Sell Rating
Bausch & Lomb Edges Higher After Confirming Sales Process
Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
Bausch + Lomb Responds to Rumors of a Potential Sale
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
Sector Update: Financial Stocks Advance Late Afternoon
Sector Update: Financial
Bausch + Lomb Shares Down on Report That Potential Buyer May Back Out
Express News | US-Listed Shares of Bausch + Lomb Down 12% After Report Blackstone Has Cooled on Taking Part in Joint Takeover Bid for Co, Citigroup Cuts to Neutral From Buy
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Market Chatter: Blackstone Withdraws From Bausch + Lomb Takeover Talks
Express News | Bausch + Lomb : Citigroup Cuts to Neutral From Buy
Press Release: Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Citi Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Cuts Target Price to $22
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating
Top Gap Ups and Downs on Monday: TSLA, NET, STLA and More
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Downgrades Bausch & Lomb to Equal-Weight, Announces $19 Price Target